Cumulatively, pro‐survival isoform switching and DFFB isoform regulation of SOX2 and MYCN may play a role in T‐ALL proliferation and survival, thus serving as a potential therapeutic option. This evidence concerns the gene SOX2 and acute lymphoblastic leukemia.